GERN

Geron Corporation announced it will release its third quarter 2026 financial results on November 4, 2026, before market open, followed by a conference call at 8:00 a.m. Eastern Time. The hematology-focused biopharmaceutical company is advancing its telomerase inhibitor imetelstat (RYTELO®), which is approved for lower-risk myelodysplastic syndromes in the US and EU, with ongoing Phase 3 trials in myelofibrosis and other blood cancers.

Bristol Myers is relying on its growth portfolio including Reblozyl, Opdivo, and other key drugs to drive top-line growth as legacy drug sales decline. Reblozyl sales reached nearly $1.3 billion in H1 2026, up 23% year-over-year, with potential for further growth from new indications. However, the company faces increasing competition from Geron's Rytelo and Keros Therapeutics' elritercept in the MDS and myelofibrosis treatment space.